Detalhe da pesquisa
1.
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Nature
; 620(7976): 1063-1070, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587335
2.
PTEN deficiency exposes a requirement for an ARF GTPase module for integrin-dependent invasion in ovarian cancer.
EMBO J
; 42(18): e113987, 2023 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37577760
3.
Mannose impairs tumour growth and enhances chemotherapy.
Nature
; 563(7733): 719-723, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30464341
4.
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
Int J Gynecol Cancer
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38760075
5.
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Int J Gynecol Cancer
; 33(8): 1253-1259, 2023 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072323
6.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(7): 919-930, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690073
7.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 277-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33357510
8.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34602290
9.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752918
10.
Metronomic oral cyclophosphamide in relapsed ovarian cancer.
Int J Gynecol Cancer
; 31(7): 1037-1044, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34016703
11.
Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management.
Int J Gynecol Cancer
; 31(2): 161-168, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33414107
12.
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Int J Gynecol Cancer
; 31(12): 1589-1594, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593565
13.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Lancet
; 394(10214): 2084-2095, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31791688
14.
Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey.
Int J Gynecol Cancer
; 30(6): 819-824, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32354792
15.
Targeting DNA repair: the genome as a potential biomarker.
J Pathol
; 244(5): 586-597, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29282716
16.
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
Int J Gynecol Cancer
; 29(9): 1396-1404, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31685558
17.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10106): 1949-1961, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916367
18.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908594
19.
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Gynecol Oncol
; 147(2): 267-275, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882436
20.
Progression-free survival in the ICON8 trial - Authors' reply.
Lancet
; 396(10253): 757, 2020 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32919511